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Abstract
Background: Asthma is characterized by a heterogeneous inflammatory profile and can be subdivided into
T(h)2-high and T(h)2-low airway inflammation. Profiling of a broader panel of airway cytokines in large unselected
patient cohorts is lacking.
Methods: Patients (n = 205) were defined as being “cytokine-low/high” if sputum mRNA expression of a particular
cytokine was outside the respective 10th/90th percentile range of the control group (n = 80). Unsupervised
hierarchical clustering was used to determine clusters based on sputum cytokine profiles.
Results: Half of patients (n = 108; 52.6%) had a classical T(h)2-high (“IL-4-, IL-5- and/or IL-13-high”) sputum cytokine
profile. Unsupervised cluster analysis revealed 5 clusters. Patients with an “IL-4- and/or IL-13-high” pattern
surprisingly did not cluster but were equally distributed among the 5 clusters. Patients with an “IL-5-, IL-17A-/F- and
IL-25- high” profile were restricted to cluster 1 (n = 24) with increased sputum eosinophil as well as neutrophil
counts and poor lung function parameters at baseline and 2 years later. Four other clusters were identified:
“IL-5-high or IL-10-high” (n = 16), “IL-6-high” (n = 8), “IL-22-high” (n = 25). Cluster 5 (n = 132) consists of patients
without “cytokine-high” pattern or patients with only high IL-4 and/or IL-13.
Conclusion: We identified 5 unique asthma molecular phenotypes by biological clustering. Type 2 cytokines cluster
with non-type 2 cytokines in 4 out of 5 clusters. Unsupervised analysis thus not supports a priori type 2 versus
non-type 2 molecular phenotypes. www.clinicaltrials.gov NCT01224938. Registered 18 October 2010.
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Background
Chronic airway inflammation has long been seen as a
general characteristic of all patients with asthma [1]. In
addition, dyspnoea, wheezing and cough are typical
asthma symptoms and result from narrowing of the
airway lumen. Corticosteroids and bronchodilators are
therefore the first choice treatment for patients with
asthma [2]. The response to these drugs is variable,
which could not only be attributed to pharmacogenetic
aspects [3]. Analysis of inflammatory cells in sputum
and bronchial biopsies revealed that eosinophilic inflam-
mation was only present in a subgroup of patients and
that its presence is associated with the beneficial re-
sponse to corticosteroids [4]. Molecular phenotyping has
further strengthened the concept of asthma as a hetero-
geneous disease [5]. Patients with a T(h)2-high profile
are found in half of the mild asthmatic patients and
reported to be responsive to steroids [6, 7]. Biomarker
research, so far, has mainly focused on T(h)2 associated
cytokines or surrogate markers of type 2 driven airway
inflammation (such as FENO or serum periostin). It
remains unclear which pathophysiological mechanisms
are driving asthma in patients with normal airway
expression of type 2 cytokine levels.
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Several other T cell related and epithelial derived cyto-
kines are found to be increased in patients with asthma
[8–11]. However, how they are associated which each
other is not fully understood. Microarray analysis of spu-
tum cells revealed 6 biomarkers that are specifically
associated with eosinophilic or neutrophilic asthma [12].
A recent cluster analysis showed 6 clinicopathobiologic
clusters with differences in lung function, sputum cellu-
lar profile, YKL-40 protein and matrixmetalloproteinases
[13]. We previously showed that sputum analysis can be
used to identify different “cytokine-high” patterns and
that these patterns are linked to lung function parame-
ters, asthma control and BMI [11, 14].
There is thus an increased awareness about the diver-
sity of the inflammatory profile amongst asthma pa-
tients. Unravelling the associations between the different
inflammatory cells and mediators might help to identify
the patients’ endotype. In the present study we aimed to
extent our previous findings in a larger population of
asthmatics and identify cytokine-based asthma clusters
in which each patient is allocated to one single cluster.
To that aim, expression of twelve sputum cytokines was




Patients (n = 296) with symptoms compatible with
asthma between 18 and 65 years were recruited amongst
those consecutively attending the outpatient clinic of
pulmonary disease or allergology of the University
Hospital Leuven. Diagnosis of asthma was confirmed based
on previous (<24 months) or current proof of reversibility
of FEV1 ≥ 12% after inhalation of salbutamol and/or a posi-
tive histamine provocation test (PC20 < 8 mg/ml). Patients
with respiratory infection 1 month or exacerbation 3
months prior to analysis were excluded. Patients were
allowed to continue daily treatment. Patients who did not
take inhaled steroids for at least 3 months were classified
as steroid-naive patients. Healthy non-symptomatic
volunteers (n = 96) were recruited amongst students and
university coworkers. A power analysis was conducted to
determine the number of asthma patients and healthy sub-
jects needed to detect a 2-fold difference in the mean
values between both groups given current knowledge on
sputum cytokine expression levels, based on our own pre-
viously published results [8, 10]. Power analysis showed
that 300 asthma patients and 100 healthy subjects were re-
quired, considering that 70% of individuals will produce a
sample that is useful for cytokine analysis. Written in-
formed consent was obtained from all patients. Study was
approved by the local ethical committee and registered on
clinicaltrials.gov (NCT01224938). Samples of 34 asthma
patients and 20 control subjects in the current study were
also previously used for analysis of sputum cytokine
mRNA patterns in asthma [11]. However, samples were re-
analyzed together with the enlarged cohort for sputum
cytokine analysis.
Lung function and clinical characteristics
Different dynamic lung volumes were measured by
spirometry (Jaeger, Carefusion): FEV1 (forced expiratory
volume in 1 second), FVC (forced vital capacity) and
FEF25–75 (forced expiratory flow at 25–75% of FVC); and
expressed as % predicted. FEV1 after 2 years was re-
trieved from medical records of patients in follow up
(see Additional file 1). FENO was measured prior to spir-
ometry by means of a chemiluminescence analyzer
(CLD88s, Ecomedics, Switzerland). Spirometry was per-
formed according to ERS criteria, before and after inhal-
ation of salbutamol 400 μg. Asthma control was assessed
by Asthma Control Test questionnaire [15]. Atopy was
assessed by skin prick test or immunocap (Phadia) for
most common aeroallergens: house dust mite, grass
pollen mixture, tree pollen mixture, cat, dog, Alternaria
alternata, Aspergillus fumigatus (HAL Allergy, Leiden).
Sputum induction and analysis
Sputum induction and processing was performed as de-
scribed previously [10, 11, 16, 17]. In brief, hypertonic
salt solution of 3, 4 and 5% respectively was nebulized
each time 7 min. Afterwards, the patient was asked to
rinse the mouth and spit the sputum in a collection
tube. Sputum total and differential cell counts were ob-
tained by cytospin (Shandon cytocentrifuge). An a priori
selected panel of T cell and innate cytokines were ana-
lyzed by by real-time (RT)-PCR: Th1 (IFN-γ), Th2 (IL-4,
IL-5, IL-13 and IL-10), Th17 (IL-17A, IL-17 F and
IL-22) and innate (IL-1β, IL-6, IL-25, and TNF). Patients
were defined as being “cytokine-low” or “cytokine-high” if
sputum mRNA expression levels of that particular cyto-
kine were outside the 10th–90th percentile value of the
current control group, respectively. Samples with an
mRNA content of <0.25 μg and <300 000 non-squamous
sputum cells were excluded. We measured cytokine
mRNA levels only in samples with β-actin mRNA
levels >10 000 copies. Cytokine mRNA levels were
measurable in 70% (205/296 patients) of all included
asthma patients and 83% (80/96 subjects) of healthy sub-
jects (see Additional file 1: Table E1).
Cluster analysis and statistics
A tertiary code (1: “cytokine-high”, −1: “cytokine-low” or
0: normal cytokine levels for a particular cytokine) was
created and used for unsupervised hierarchical cluster
analysis. Ward’s minimum-variance clustering method
was used to create the best set of clusters for each pos-
sible number of clusters, and we decided upon the
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number of clusters to proceed by combining the cubic
clustering criterion and pseudo F and T2 statistics [18,
19]. A tree representing the patients grouped in clusters
was created. Cluster analysis was performed in SAS, ver-
sion 9.3 (SAS Institute, Cary, NC, USA).
Further statistical analyses were performed with
Graphpad Prism V for Macintosh (Graphpad Software
Inc., San Diego, USA) by use of Kruskal-Wallis, Dunn’s
or Tukey multiple comparison test (as post-test) and
Mann–Whitney U test when appropriate. ANOVA and
T-test were performed if data were normally distributed.
Chi squared analysis was used to compare proportions
between different groups. Normality was analyzed by
Kolmogorov-Smirnov test. Mean or median levels of
clinical and inflammatory parameters in different clusters
were compared to the actual mean or median of the total
group of asthmatics. For multivariate analysis of factors
that may contribute to cluster determination, multinomial
logistic regression analysis was applied. A difference was
considered to be significant when p < 0.05.
Results
Subjects
Subject characteristics are presented in Table 1. Sensi-
tisation to aeroallergens was more prevalent amongst
asthmatic patients (76%) than controls (35%) (Table 1).
Active smoking was recorded in 25 asthmatics (12%).
BMI was higher in asthmatics compared to controls
(p < 0.0001). Twenty percent of patients (n = 41) were
steroid-naive. Fifty-three percent of asthmatics had a Th2-
high profile (sputum IL-4-, IL-5- and/or IL-13-high).
Sputum cytokine profiles in asthma patients: cluster
analysis
Sputum cytokine mRNA 10th and 90th percentile values
of expression levels in healthy subjects (n = 80) were cal-
culated to determine lower and upper cut-off levels for
the various cytokines (Table 2). Unsupervised hierarch-
ical clustering was applied to identify clusters of patients
with a similar sputum “cytokine-low or -high” profile.
Five clusters were selected according to cubic clustering
criterion (CCC) and pseudo F and T2 statistics (see
Additional file 1: Figure E1A). Patients in the first cluster
(n = 24) presented with an “IL-5-, IL-10-, IL-25-, IL-17A-
and IL-17 F-high” profile. Patients in the second cluster
(n = 16) presented with an “IL-5- and/or IL-10-high” pro-
file but normal IL-17 F levels. Patients in cluster 3 (n = 8)
had an “IL-6-high” profile. Patients in cluster 4 (n = 25)
presented with an “IL-22-high” profile of which half were
also “IL-1β-high”. Cluster 5 (n = 132) was the largest clus-
ter and consists of patients with normal levels of the
former cytokines (n = 123). The proportion of patients with
an “IL-4- or IL-13-high” profile was equally distributed
among the 5 clusters. Absolute sputum cytokine levels
among the 5 clusters are shown in Fig. 1. Patients with a
“TNF-low” profile were significantly overrepresented in
Table 1 Subject characteristics
Asthma (n = 205) Healthy (n = 80) P value
Subjects (n=) 205 80
Age (years) 30–40–51 23–27–42 <0.0001
Gender (M/F) 96/112 30/50 0.09
Body Mass Index 21.9–24.4–28.1 20.4–22.3–24.5 <0.0001
Active smoking (%) 25 (12%) 2 (3%) 0.007
Allergy (%) 139 (76%) 23 (35%) <0.0001
Steroid-naive 41 (20%) NA
Inhaled steroids only 142 (69%) NA
Inhaled and oral steroids 22 (11%) NA
FEV1 % predicted (%) 94.6 ± 19.0 108.9 ± 14.2 <0.0001
FEV1/FVC (%) 72.3 ± 11.4 81.7 ± 6.5 <0.0001
FENO (ppb) 13.4–22.0–38.6 10.3–16.2–22.9 0.0004
Sputum eosinophils (%) 0.0–1.0–4.0 0.0–0.0–0.4 <0.0001
Sputum neutrophils (%) 13.0–35.0–58.8 13.8–25.4–41.1 0.02
Sputum total cell count (x106 cells) 0.8–1.3–2.5 0.9–1.4–2.0 0.48
Asthma Control test (/25) 17.0–20.5–23.0 25–25–25 <0.0001
Clinical, lung function and inflammatory parameters in asthmatic patients and healthy subjects. Normally distributed data were represented as mean ± standard
deviation and analyzed by T-test. Data that were not normally distributed were represented as median and 25–75% (interquartile range) percentile and analyzed
by Mann-Whitney test. FEV1 Forced Expiratory Volume in 1 second, FVC Forced Vital Capacity, FENO Fraction of exhaled Nitric Oxide
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cluster 1 and 5 compared to the other clusters (p = 0.01),
whereas those with an “IL-1β-low” profile were significantly
overrepresented in cluster 5 (p < 0.0001).
Validation of the number of clusters and the patients’
cytokine profile in each cluster was performed by
splitting the total cohort into 2 groups and repeating the
analysis on each half separately. Analysis of the esti-
mated number of cluster (by Ward’s method) showed 5
clusters for the first group and 6 for the second group.
Cluster analysis was performed for 5 clusters for sake of
consistency in both groups. To compare the cytokine-
high profiles among the different clusters, radar graphs
were used, representation the proportion of patients
with a particular cytokine-high expression profile
(Additional file 1: Figure E2). The five clusters were re-
markably similar in both analyses, except for the IL-22-
Table 2 Sputum cytokine mRNA levels in control and asthmatic individuals






IFN-γ 0.12 – 0.27 – 1.20 0.07 – 0.30 – 1.26 0.35 0.42 22 (11%) 38 (19%)
IL-4 0.00 – 0.00 – 0.00 0.00 – 0.00 – 3.14 <0.0001 0.0006 81 (40%) 0
IL-5 0.16 – 1.41 – 6.89 0.15 – 1.36 – 10.3 0.49 0.49 30 (15%) 22 (11%)
IL-13 0.00 – 0.00 – 1.07 0.00 – 0.27 – 4.10 <0.0001 0.0006 56 (27%) 0
IL-10 0.42 – 0.96 – 2.34 0.44 – 1.20 – 3.52 0.018 0.04 41 (20%) 19 (9%)
IL-17A 0.27 – 1.73 – 9.49 0.21 – 1.62 – 12.55 0.26 0.35 26 (13%) 33 (16%)
IL-17 F 0.25 – 2.3 – 14.02 0.16 – 1.99 – 16.41 0.15 0.3 23 (11%) 34 (17%)
IL-22 0.00 – 0.17 – 1.60 0.00 – 0.14 – 2.06 0.49 0.49 29 (14%) 0
IL-25 0.34 – 2.37 – 15.28 0.19 – 2.18 – 17.78 <0.0001 0.0006 26 (13%) 34 (17%)
TNF 0.07 – 0.25 – 1.95 0.03 – 0.14 – 1.95 0.22 0.35 7 (3%) 49 (24%)
IL-6 0.00 – 0.05 – 0.19 0.00 – 0.03 – 0.17 0.0002 0.0006 16 (8%) 28 (14%)
IL-1β 0.24 – 0.50 – 1.15 0.08 – 0.48 – 1.68 0.25 0.35 35 (17%) 51 (25%)
Sputum cytokine mRNA levels were represented as median and 10th–90th percentile value and analysis between both groups was performed by Mann-Whitney
test. *P value after correction for multiple comparison (Benjamini-Hochberg correction)
Fig. 1 Absolute sputum cytokine levels among different clusters of asthmatics. Patients were clustered based on their sputum cytokine-high or
cytokine-low profile. Asthmatics are divided into 5 clusters: cluster 1: n = 24, IL-5-high and IL-17 F-high; cluster 2: n = 15, IL-5-high and IL-17 F-low;
cluster 3: n = 8, IL-6-high; cluster 25: n = 15, IL-22-high; cluster 5: n = 132. Absolute sputum cytokine levels were shown as 10-90th percentile box
and whiskers plots. The dotted line represents the 10th or 90th percentile value of control individuals
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high cluster, which could not be found in one of the
groups. If for one of the groups 6 clusters were build (as
suggested by Ward’s method) then all five main clusters
remained and only 1 patient was separated from the
cluster with 77 patients.
Evaluation of lung function and airway inflammation
The group with an “IL-5-, IL-10-, IL-17A/F-, IL-25-high”
profile (cluster 1) had significantly lower FEV1 % predicted
compared to the mean of all asthmatics (p = 0.026; Fig. 2a
and Table 3). Patients in cluster 1 also had significantly
higher chance to have a FEV1 % predicted ≤85% (OR: 2.7,
95% CI: 1.1-6.4). A similar trend was found for FEF25–75, %
predicted levels in cluster 1 (p = 0.079; Fig. 2b).
After 2 and 3 years (p < 0.05), FEV1 % predicted was sig-
nificantly lower in cluster 1 compared to the mean of all
asthmatics (Fig. 2c and see Additional file 1: Figure E3).
FENO levels of patients in cluster 1 were significantly
higher compared to the median of all asthmatics (p = 0.044;
Fig. 2f). Sputum eosinophil percentages in parallel were sig-
nificantly higher in cluster 1 but also in cluster 5 compared
to the median of all asthmatics (p = 0.01 and p = 0.003;
Fig. 2d and Table 3). Sputum neutrophil percentages were
significantly higher in cluster 1 and 4 (p = 0.039 and
p = 0.007; Fig. 2e) and significantly lower in cluster 5
(p = 0.018; Fig. 2e) compared to the median of all
asthmatics. Both cluster 1 and 4 had significantly higher
sputum neutrophil percentages compared to cluster 5
(p < 0.05 and p < 0.01; Fig. 2e). A schematic representation
of the clusters based on their sputum eosinophil and neu-
trophil profile is visualized in Additional file 1: Figure E4.
Patient cluster decision tree
A discriminative decision tree to classify all asthma patients
individually into the cited clusters was developed afterwards
(Fig. 3). Patients with an “IL-5- and IL-17 F-high” profile, ir-
respective of expression of other cytokines, were classified
in cluster 1 (n = 24). Patients with an “IL-5- and/or IL-10-
high” but not an “IL-17 F-high” profile, were classified in
cluster 2 (n = 16). In the next step, patients who have
normal levels for the previous cytokines but “IL-22-
high”, were assigned to cluster 4 (n = 25). Next, patients
with an “IL-6-high profile”, are classified in cluster 3 (n =
8). All other patients were grouped in cluster 5 (n = 132).
This group consists of patients with normal levels of the
previous cytokines. By use of this decision tree, all patients
could be classified in one single cluster without overlap.
Sputum cytokine profiles in steroid-naive asthma patients
Forty-one patients did not use inhaled steroids daily.
Patient characteristics are shown in Additional file 1:
Table E1. Among them, six clusters (according to CCC,
pseudo F and t2 statistics; Additional file 1: Figure E1B)
could be identified: cluster I (similar profile to cluster 1)
Fig. 2 Lung function and airway inflammatory parameters. Asthmatics are divided into 5 clusters: cluster 1: n = 24, IL-5-high and IL-17 F-high; cluster 2:
n = 15, IL-5-high and IL-17 F-low; cluster 3: n = 8, IL-6-high; cluster 25: n = 15, IL-22-high; cluster 5: n = 132. Data are represented as mean ± standard
deviation (a-c) or median ± interquartile range (d-f). Data are compared between the 5 clusters by Kruskal-Wallis and Dunn’s Multiple comparison test
(∞: p < 0.05). Data of each cluster was compared to the mean (a-c) or median (d-f) of the total group (*: p < 0.05, **:p < 0.01; ***:p < 0.001)
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Table 3 Characteristics of patient clusters
CLUSTER 1 2 3 4 5 P value
Subjects (n=) 24 16 8 25 132
Age (years) 44.0 ± 13.4 47.3 ± 14.1 39.0 ± 15.4 38.0 ± 12.7 40.2 ± 12.7 0.14
Gender (M/F) 12/12 6/10 4/4 11/14 62/70 0.95
Body Mass Index 22.5–26.8–28.8 21.2–25.4–29.9 20.7–23.5–30.9 21.9–23.6–26.0 21.8–24.3–28.7 0.55
Active smoking (%) 9 0 0 19 19 0.27
Atopy (%) 73 62 88 73 80 0.54
Steroid-naive (%) 8 18 12 20 23 0.82
Inhaled steroids only (%) 79 75 50 68 68 0.58
Inhaled and oral steroids (%) 13 7 38 12 9 0.15
FEV1, % predicted 86.0 ± 17.7
† 93.9 ± 17.5 95.6 ± 18.8 95.2 ± 21.4 96.1 ± 18.7 0.21
FEV1/FVC 69.0 ± 12.0 72.5 ± 8.1 71.3 ± 13.1 71.3 ± 13.4 73.1 ± 11.3 0.57
PEF, % predicted 90.0 ± 19.7 91.8 ± 18.5 96.9 ± 26.6 88.8 ± 26.7 97.5 ± 19.5 0.30
FEF25–75, % predicted 53.5 ± 25.6 55.5 ± 23.0 67.2 ± 41.4 67.8 ± 35.4 67.2 ± 30.6 0.29
FENO (ppb) 16.8–27.2–48.1
† 12.1–6.7–29.5 16.1–27.9–43.3 13.9–24.3–55.1 13.3–21.2–37.2 0.46
Sputum eosinophils (%) 0.6–2.0–31.1† 0.2–1.0–8.0 0.0–1.0–4.0 0.0–0.8–2.0 0.0–1.0–4.0††† 0.36
Sputum neutrophils (%) 23.5–51.9–81.6*,† 29.5–64.0–73.8 22.0–32.0–62.4 37.0–55.0–77.9**,†† 11.8–24.8–49.5† <0.0001
Clinical, lung function and inflammatory parameters in different asthma patients clusters defined by their sputum cytokine profile. Cluster 1: n = 24; IL-5-high and
IL-17A-high, cluster 2: n = 16; IL-5-high and IL-10-high and IL-17 F-low, cluster 8: n = 15; IL-6-high, cluster 4: n = 25; IL-22-high, cluster 5: n = 132; normal levels of
the previous cytokines with or without an IL-1β or TNF low profile. Normally distributed data were represented as mean ± standard deviation and analyzed by
ANOVA. Data that were not normally distributed were represented as median and 25–75% (interquartile range) percentile and analyzed by Kruskal-Wallis test.
Dunn’s Multiple Comparison test was used as a post hoc test. *,**p < 0.05, p < 0.01 respectively compared to cluster 5, †,††,†††p < 0.05, p < 0.01 and p < 0.001
respectively compared to mean/median level in asthmatics. FEV1 Forced Expiratory Volume in 1 second, FVC Forced Vital Capacity, PEF Peak Expiratory Flow,
FEF25–75% Forced expiratory Flow at 25–75% interval, FENO Fraction of exhaled Nitric Oxide
Fig. 3 Decision tree with patient clusters of all asthmatics. Patients with an “IL-17 F-high and IL5-high” profile, irrespective of expression of other
cytokines, were labelled as cluster 1 (n = 24). Patients with an “IL-5-high or IL-10-high” but not an “IL-17 F-high” profile, were identified as cluster
2 (n = 16). In the next step, patients who had normal levels of the previous cytokines but were “IL-22-high”, were assigned to cluster 3 (n = 25).
Patients with an “IL-6-high profile” were labelled as cluster 4 (n = 8). All other patients were grouped in cluster 5 (n = 132). *: This group consists
of patients with normal levels of the previous cytokines with or without an “IL-1β- or TNF-low” profile (n = 49 and n = 83, respectively)
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“IL-5-, IL-25-, IL-17A-, IL-17 F- and IL-10-high” (n = 2),
cluster II (similar to cluster 2) “IL-5- and/or IL-10-high”
but “IL-17 F-low” (n = 2), cluster III “IL-4-high” (n = 5),
cluster IV “IL-4- and IL-13-high” (n = 9), cluster V (simi-
lar profile to cluster 4) “IL-22-high” (n = 3) and cluster
VI (similar profile to cluster 5) normal cytokine levels or
“IL-1β- or TNF-low” (n = 20). Patients with an “IL-6-
high” profile (n = 2) did not cluster and were found in
cluster IV and V. Absolute sputum cytokine mRNA
levels among the different clusters were shown in Fig. 4.
Among steroid-naive patients, FEV1 % predicted was
significantly lower in those with an “IL-4- and IL-13-high”
profile (cluster IV) compared to the mean of all asthmatics
(p = 0.025; Fig. 5a and Additional file 1: Table E1).
Sputum eosinophil percentages were significantly in-
creased in patients with an “IL-4- and IL-13-high” pro-
file compared to the median of all asthmatics (p = 0.04;
Fig. 5c), while no significant differences were found for
sputum neutrophils (Fig. 5d). FENO levels did not sig-
nificantly differ among the 6 clusters but were highest in
cluster III and IV (Fig. 5e).
Multivariate analysis of confounding factors
In order to assess whether confounding factors such as
age, gender, BMI and steroid use may have influenced
the classification of the patient clusters, these factors
were studied by multinomial logistic regression analysis,
both separately in univariate analyses and together in a
multivariate model. None of the factors included in the
univariate analysis contributed to the classification of
the patient clusters (data not shown). Multivariate logis-
tic regression did not suggest an association either be-
tween any of these factors and the identified clusters
(Additional file 1: Table E3; p = 0.52).
Discussion
We have identified 5 patient clusters based on sputum
cytokine-high profiles in a large unselected asthma co-
hort. Remarkably, type 2 cytokines, IL-4 and IL-13, did
not cluster but were found in an equal proportion of pa-
tients throughout the 5 clusters. This points towards
considerable heterogeneity amongst patients with type 2
inflammation. Many patients (cluster 1–4) show add-
itional inflammation on top of IL-4 and IL-13. That
might be the reason why patients with an “IL-4- and/or
IL-13-high” profile do not show up as a separate cluster.
In contrast, steroid-naive patients can either have milder
or more recently developed disease. This could explain
why they might present with limited additional cytokine-
high expression on top of their IL-4-/IL-13-high expres-
sion. Hence, steroid-naive patients with an “IL-4- and/or
IL-13-high” profile cluster together.
Patients with high IL-5 mRNA expression, on the con-
trary, were restricted to cluster 1 (n = 24) and expressed
high IL-17 F mRNA levels. Patients in this cluster also
have an “IL-17A-, IL-25- and IL-10-high” profile, but in
contrast to IL-5 and IL-17 F, these cytokines were not
required for identification of the cluster. The identifica-
tion of this cluster is in agreement with our earlier ob-
servation that sputum IL-5, IL-25 and IL-17A mRNA
Fig. 4 Absolute sputum cytokine levels among different clusters of steroid-naive asthmatics. Patients were clustered based on their sputum
cytokine-high or cytokine-low profile. Absolute sputum cytokine levels were shown as 10–90th percentile box and whiskers plots. The dotted line
represents the 10th or 90th percentile value of control individuals
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levels are increased simultaneously in a subgroup of
asthmatics [11]. At first, this association was unexpected,
as we hypothesized that IL-5 would have been increased
in eosinophilic asthma, whereas IL-17A might be
increased in neutrophilic asthma. Recently, Hinks and
colleagues also demonstrated an association between
BAL IL-17A and eosinophil counts in asthmatics [20].
Patients in cluster 1 furthermore had increased sputum
eosinophils as well as neutrophils, matching with the
IL-5- and IL-17-high cytokine profile. These patients had
worse lung function parameters and 2.7 higher odds to
have FEV1 ≤ 85%. Analysis of lung function parameters
after 2 and 3 years still showed worst FEV1 suggesting per-
sistence of airway obstruction in these patients. A pro-
spective longitudinal study however should help to define
the lung function trajectory of those patients.
Patients in cluster 2 had high IL-10 and some had high
IL-5 (as in cluster 1) but normal IL-17A/F mRNA levels,
and these patients had slightly better lung function
parameters compared to cluster 1, indicating that high
IL-17 F expression associates with worse lung function
parameters. Patients in cluster 3 had high IL-6 sputum
mRNA levels, whereas cluster 4 is characterized by high
IL-1β and IL-22 mRNA. These clusters represent pa-
tients with normal sputum eosinophils in most cases,
whereas neutrophils were increased in patients with high
IL-1β and IL-22. Single nucleotide polymorphisms in the
IL-6 receptor gene were shown to be associated with in-
creased risk for asthma [21]. Patients in cluster 3 might
therefore be good candidates for trials with anti-IL6
monoclonal antibodies. Strikingly, IL-22 identified a sep-
arate patient cluster (cluster 4) and was not increased in
patients with high IL-17A/F (cluster 1). This was unex-
pected as IL-22 is thought to be produced by Th17 cells,
which we consider responsible for IL-17A/F production
in this cluster. Different other cells may however also
produce IL-22: alveolar macrophages, dendritic cells,
Th22 cells and innate lymphoid cells [22–24]. Th22 cells
not producing IL-17A could be identified recently [25].
IL-22 expression was reported to be increased in periph-
eral blood mononuclear cells (PBMC) from both chil-
dren and adults with asthma [26, 27]. In another study,
IL-22 attenuated IL-25 production by lung epithelial
cells and inhibited antigen-induced eosinophilic airway
inflammation, underscoring that IL-22 might exert pro-
tective effects in asthma [28]. However, in contrast to
the idea that IL-22 might be beneficial in asthma, ana-
lysis of patients in cluster 4 did not show significantly
better lung function than the other groups. Those pa-
tients had rather high sputum neutrophils and normal
sputum eosinophil counts.
A heterogeneous group of patients was found in clus-
ter 5. More than half of the patients had no increased
cytokine expression or sputum granulocytes. A low de-
gree of inflammation is thus found in these patients,
which may correspond to the paucigranulocytic phenotype
[29]. In contrast, 40% of patients had an “IL-4- and/or
IL-13-high” profile, which is equal to the proportion
Fig. 5 Lung function and airway inflammatory parameters of steroid-naive asthmatics. Steroid-naive asthmatics are divided into 6 clusters: cluster
I: n = 2, IL-5-high and IL-17 F-high; cluster II: n = 2, IL-5-high or IL-10-high and IL-17 F-low; cluster III: n = 5, IL-4-high; cluster IV: n = 10, IL-4-high
and IL-13-high; cluster V: n = 3, IL-22-high; cluster VI: n = 20. Data are represented as mean ± standard deviation (a-b) or median ± interquartile
range (c-e). FEV1% predicted levels of each cluster were compared to the mean of the total group (*: p < 0.05)
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found in the other clusters. However, in this cluster, this
occurs without elevation of any other T helper or pro-
inflammatory cytokines, which discriminates them from
the other clusters. Cluster 5 had rather low levels of
IFN-γ, TNF and IL-1β in sputum. Sputum eosinophils
were increased in a subgroup of patients within cluster 5.
This could be attributed to patients with an “IL-4- and/or
IL-13-high” profile, as these patients have significantly
higher sputum eosinophils and FENO levels compared to
patients with an normal levels of IL-4 and/or IL-13 profile
(data not shown). In a study by Fahy and coworkers, a
qPCR-based metric combining sputum cytokine expres-
sion of IL-4, IL-5 and IL-13 was used to distinguish be-
tween T(h)2-high and T(h)2-low asthmatics [7, 30]. In our
hands, co-expression of all three cytokines is only found
in a limited proportion of patients located in cluster 1.
The predominant cytokine-high profile in steroid-
naive patients was “IL-4- and/or IL-13high”. In contrast
to steroid-treated patients, expression of most of the
other cytokines was equal to that found in controls.
Typical T(h)2 driven inflammation with high IL-4 and
high IL-13 expression was associated with high sputum
eosinophils. These patients might be the group of
patients that will be responsive to therapy with inhaled
steroids. On the other hand, high IL-5 expression is
associated with high IL-17A/F expression and is linked
to high sputum eosinophils and neutrophils, which
might be refractory to inhaled steroids. This however
still has to be proven.
Patients who are less symptomatic or less severe pa-
tients are not always able to expectorate sputum upon
nebulization with hypertonic saline. This might have led
to an underestimation of patients with a paucigranulocy-
tic phenotype or normal cytokine expression in sputum.
In addition, longitudinal follow up of patients is required
to evaluate reproducibility and responsiveness to treat-
ment of sputum cytokine expression.
Cytokine profiling of airway samples might help in
future to decide upon the biological treatment that fits
best for each individual patient [31, 32]. Determination
of a panel of cytokines will be required since absence or
presence of type 2 inflammation will not show whether
to give anti-IL-5, anti-IL-4, anti-IL-13 or others. More-
over, since several cytokines might be elevated simultan-
eously in the same patient, blocking shared cytokine
receptors (e.g.: IL-4Rα for IL-4 and IL-13 or IL-17RA
for IL-17A, IL-17 F and IL-25) or pathways might be a
better strategy than monoclonal antibodies that block
only 1 cytokine.
Conclusion
We here defined 5 asthma patient clusters based on spu-
tum cytokine expression, which underscores the hetero-
geneity in airway inflammation among different asthma
patients. When unsupervised cluster analysis is applied,
a priori classification of type 2 versus non-type 2 mo-
lecular phenotypes does not show up. Determination of
eosinophilic inflammation might not be sufficient and
needs to be extended with detailed analysis of the spu-
tum cytokine profile in order to decide upon the right
anti-cytokine treatment.
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